<DOC>
	<DOCNO>NCT02656394</DOCNO>
	<brief_summary>To evaluate safety efficacy 0.5 % GL101 topical gel administer twice daily 28 day ameliorate adverse ocular side effect patient ongoing treatment glaucoma medication .</brief_summary>
	<brief_title>Amelioration Adverse Ocular Side Effects Glaucoma Medications Glaucoma Patients Using Topical GL101</brief_title>
	<detailed_description>The study assess safety efficacy new treatment ocular surface disease associate use glaucoma medication .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<criteria>1 . Male female race , least 18 year age Visit 1 Screening . 2 . Has provide verbal write informed consent . 3 . Be able willing follow instruction , include participation study assessments visit . 4 . Currently treat glaucoma use least two medication , willing continue regime . 5 . Suffers least two symptom GLIA™ Glaucoma Medication Ocular Side Effect Symptoms Questionnaire severity 2 ( moderate ) . 6 . If woman childbearing potential , negative urine pregnancy test Visit 1 use adequate method birth control throughout study period . 1 . Comorbidity severe chronic eye condition judgment investigator interfere study assessment , corneal opacity scar , dystrophy , epithelial scarring , infection , blood clot , etc . 2 . Best correct visual acuity ( BCVA ) baseline &lt; 20/200 . 3 . Has condition history , opinion investigator , may interfere significantly subject 's participation study . 4 . A woman pregnant , nurse infant , plan pregnancy . 5 . Has know adverse reaction and/or sensitivity study drug component . 6 . Routine use ( twice week ) chlorinate swim pool . 7 . Unwilling unable cease use follow medication study period : Topical ocular cyclosporine ( e.g . Restasis® ) , antihistamine , antipsychotic , eye gel . 8 . Currently enrol investigational drug device study use investigational drug device within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ocular surface disease</keyword>
	<keyword>glaucoma medication</keyword>
</DOC>